Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any disorder that features disrupted cell proliferation. Includes hyperplasia, neoplastic syndrome and isolated neoplasm diseases as well as precancerous conditions.
Biomarker and diagnostic research for cancer or benign tumor has been reported in the published literature.
782 clinical trials registered, 187 recruiting. Interventions under study include drug therapy, other interventions, procedural interventions, and biologic therapy. Pipeline includes 9 PHASE4, 50 PHASE3, 131 PHASE2. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06206863](https://clinicaltrials.gov/study/NCT06206863) |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 3:00 PM UTC
Community-Based Physical Activity Intervention for Underserved Cancer Survivors |
NA |
Roswell Park Cancer Institute |
RECRUITING |
[NCT07303816](https://clinicaltrials.gov/study/NCT07303816) | Statins to Prevent Cancer Associated Blood Clots | PHASE4 | Brigham and Women's Hospital | RECRUITING |
[NCT07204535](https://clinicaltrials.gov/study/NCT07204535) | Post-TRaUmatic STress Disorder Induced by Gynecological Brachytherapy | — | Centre Paul Strauss | RECRUITING |
[NCT01137643](https://clinicaltrials.gov/study/NCT01137643) | Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer | — | UNC Lineberger Comprehensive Cancer Center | RECRUITING |
[NCT05549661](https://clinicaltrials.gov/study/NCT05549661) | Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms | PHASE1 | Mayo Clinic | RECRUITING |
300 publications have been identified in PubMed for cancer or benign tumor. Kisho has analyzed 207 by research type. Research spans Review / Meta-Analysis (47%), Basic Science / Preclinical (18%), and Diagnostic / Biomarker (13%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 97 | 47% |
Laboratory research | 38 | 18% |
Testing and diagnosis research | 27 | 13% |
Patient case studies | 18 | 9% |
Disease patterns and progression | 16 | 8% |
New treatment approaches | 7 | 3% |
Clinical study results | 3 | 1% |
Other research | 1 | 0% |
Zhong M (2026). [PMID: 41715885](https://pubmed.ncbi.nlm.nih.gov/41715885/). *Biomark Med*. [Diagnostic / Biomarker]
Mali WPTM (2026). [PMID: 41841292](https://pubmed.ncbi.nlm.nih.gov/41841292/). *Ned Tijdschr Geneeskd*. [Review / Meta-Analysis]
Rukonge PA (2026). [PMID: 41453552](https://pubmed.ncbi.nlm.nih.gov/41453552/). *Crit Rev Oncol Hematol*. [Review / Meta-Analysis]
Sohal P (2026). [PMID: 42167839](https://pubmed.ncbi.nlm.nih.gov/42167839/). *Adv Cancer Res*. [Review / Meta-Analysis]
Conard AM (2026). [PMID: 41997123](https://pubmed.ncbi.nlm.nih.gov/41997123/). *Cell*. [Review / Meta-Analysis]
Hanga AH (2026). [PMID: 41569190](https://pubmed.ncbi.nlm.nih.gov/41569190/). *Asian Pac J Cancer Prev*. [Epidemiology / Natural History]
Apostolov E (2026). [PMID: 41879555](https://pubmed.ncbi.nlm.nih.gov/41879555/). *Cancer Res*. [Clinical Trial Publication]
Stanković ZB (2026). [PMID: 41671822](https://pubmed.ncbi.nlm.nih.gov/41671822/). *Best Pract Res Clin Obstet Gynaecol*. [Review / Meta-Analysis]
Fındık DG (2026). [PMID: 42025117](https://pubmed.ncbi.nlm.nih.gov/42025117/). *An Bras Dermatol*. [Basic Science / Preclinical]
Colombo A (2026). [PMID: 41760302](https://pubmed.ncbi.nlm.nih.gov/41760302/). *In Vivo*. [Review / Meta-Analysis]